申请人:KOWA COMPANY, LTD.
公开号:US20140309207A1
公开(公告)日:2014-10-16
The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic β-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes.
A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt:
[wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group;
R
1
and R
2
, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C
1-6
alkyl group, a C
6-10
aryl group, a cyano group, a C
1-6
alkyl group optionally having a substituent, a C
2-6
alkenyl group optionally having a substituent, etc.; R
3
represents a hydrogen atom, a C
1-6
alkyl group optionally having a substituent, etc.; and R
4
represents a hydrogen atom, a halogen atom, a C
1-6
alkyl group optionally having a substituent, etc.]
本发明提供了一种新型化合物,其通式(1)如下所示,具有在肝脏和胰岛β细胞中激活葡萄糖激酶的作用,并可用作预防和/或治疗由高血糖引起的疾病,如糖尿病的药物。该通式(1)表示的螺环吲哚化合物,或其盐,或化合物或盐的溶剂:[其中环A代表含氮的5-10成员杂环基;R1和R2,相同或不同,分别代表氢原子,卤原子,卤代C1-6烷基,C6-10芳基,氰基,C1-6烷基,可选取代基,C2-6烯基,可选取代基等;R3代表氢原子,C1-6烷基,可选取代基等;R4代表氢原子,卤原子,C1-6烷基,可选取代基等。]